OliX Pharmaceuticals, Inc (KOSDAQ: 226950)

Market Cap	286.01B
Revenue (ttm)	17.90B
Net Income (ttm)	-19.72B
Shares Out	16.97M
EPS (ttm)	-1,246.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,349
Open	16,840
Previous Close	16,840
Day's Range	15,450 - 17,090
52-Week Range	8,280 - 25,550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headqua...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 72
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226950

Financial Performance

In 2023, OliX Pharmaceuticals's revenue was 17.06 billion, an increase of 83.09% compared to the previous year's 9.32 billion. Losses were -19.10 billion, -2.02% less than in 2022.